a detailed study on complaints, drug recall, returned goods and waste disposal is studied here in the presentation for the students of sixthe semester b.pharm following the PCI syllabus.
COMPLAINTS
TOPIC COVERED
1.Definition
2.Principle
3.Need for complaint handling system
4.Objectives
5.Responsibility
6.Type of complaints (CRITICAL,MAJOR ,MINOR)
7.Key for handling complaint
8.Content of product complaint data sheet
9.Steps involved in handling of complaint
10.Recordings of complain
Document Maintenance in Pharmaceutical IndustryNAKUL DHORE
Document Maintenance in Pharmaceutical Industry.
By_ NAKUL DHORE
❖ Introduction
❖ Batch Formula Record
❖ Master Formula Record
❖ SOPs
❖ Quality Audit
❖ Quality Review & Quality Documentation
❖ Reports & Documents
❖ Distribution Records
❖ MCQs
Quality Assurance
As per B.PHARM 3rd Year Semester-6
(PCI Syllabus New)
COMPLAINTS
TOPIC COVERED
1.Definition
2.Principle
3.Need for complaint handling system
4.Objectives
5.Responsibility
6.Type of complaints (CRITICAL,MAJOR ,MINOR)
7.Key for handling complaint
8.Content of product complaint data sheet
9.Steps involved in handling of complaint
10.Recordings of complain
Document Maintenance in Pharmaceutical IndustryNAKUL DHORE
Document Maintenance in Pharmaceutical Industry.
By_ NAKUL DHORE
❖ Introduction
❖ Batch Formula Record
❖ Master Formula Record
❖ SOPs
❖ Quality Audit
❖ Quality Review & Quality Documentation
❖ Reports & Documents
❖ Distribution Records
❖ MCQs
Quality Assurance
As per B.PHARM 3rd Year Semester-6
(PCI Syllabus New)
A detailed study of the organisation and personnel involved in the pharmaceutical industry. These are involved in the guidelines of Good Manufacturing Practices.
General Principles of Analytical Method of Validation.pdfTamannaKumari8
Validation is the process of establishing documentary evidence demonstrating that a procedure, process, activity carried out in
testing and then production maintain the desirable level of compliance all stages.
The process of providing the analytical procedure is acceptable or its intended us.(ICH Q
Quality control on secondary packaging materialsAnupriyaNR
Presentation on quality control tests for the secondary packaging materials. Includes the materials used for secondary packaging, ideal properties of the secondary packaging material and various test procedures used for the quality control of the packaging materials.
PHARMACEUTICAL QUALITY ASSURANCE SIXTH SEMSTER B PHARM
Introduction, definition and general principles of calibration, qualification
and validation, importance and scope of validation, types of validation, validation master plan. Calibration of pH meter, Qualification of UV-Visible spectrophotometer, General principles of Analytical
method Validation.
QUALIFICATION OF UV-VISIBLE SPECTROPHOTOMETER, FTIR, DSC, HPLCAnupriyaNR
Analytical method qualification consists of a simplified evaluation of a subset of validation characteristics with a goal to demonstrate that an analytical method is scientifically sound and suitable for its intended use. In contrast to validation, analytical method qualification is performed without predefined acceptability criteria. Qualification may be performed as a prerequisite to method validation, or when an assay for product knowledge has not yet been established as a test for a critical product quality attribute. Qualification of equipment is pre-requisite for validation of the process in which the equipment is being used. Many types of equipment have measuring devices on them. Calibration of measuring devices is a part of qualification. Calibration of measuring devices is important, as the data is often collected through them. If the data collected is not from measuring devices that have been calibrated, the data cannot be relied upon. Thus the whole validation exercise can be questioned.
Q.R are planned and documented by an inspections of a review item
The review item may be a product, a group of related products or a part of a product
If the error identified earlier the cost of implication is less and the penalty for failing to conduct adequate reviews.
A detailed study of the organisation and personnel involved in the pharmaceutical industry. These are involved in the guidelines of Good Manufacturing Practices.
General Principles of Analytical Method of Validation.pdfTamannaKumari8
Validation is the process of establishing documentary evidence demonstrating that a procedure, process, activity carried out in
testing and then production maintain the desirable level of compliance all stages.
The process of providing the analytical procedure is acceptable or its intended us.(ICH Q
Quality control on secondary packaging materialsAnupriyaNR
Presentation on quality control tests for the secondary packaging materials. Includes the materials used for secondary packaging, ideal properties of the secondary packaging material and various test procedures used for the quality control of the packaging materials.
PHARMACEUTICAL QUALITY ASSURANCE SIXTH SEMSTER B PHARM
Introduction, definition and general principles of calibration, qualification
and validation, importance and scope of validation, types of validation, validation master plan. Calibration of pH meter, Qualification of UV-Visible spectrophotometer, General principles of Analytical
method Validation.
QUALIFICATION OF UV-VISIBLE SPECTROPHOTOMETER, FTIR, DSC, HPLCAnupriyaNR
Analytical method qualification consists of a simplified evaluation of a subset of validation characteristics with a goal to demonstrate that an analytical method is scientifically sound and suitable for its intended use. In contrast to validation, analytical method qualification is performed without predefined acceptability criteria. Qualification may be performed as a prerequisite to method validation, or when an assay for product knowledge has not yet been established as a test for a critical product quality attribute. Qualification of equipment is pre-requisite for validation of the process in which the equipment is being used. Many types of equipment have measuring devices on them. Calibration of measuring devices is a part of qualification. Calibration of measuring devices is important, as the data is often collected through them. If the data collected is not from measuring devices that have been calibrated, the data cannot be relied upon. Thus the whole validation exercise can be questioned.
Q.R are planned and documented by an inspections of a review item
The review item may be a product, a group of related products or a part of a product
If the error identified earlier the cost of implication is less and the penalty for failing to conduct adequate reviews.
B PHARAM 6TH SEM
PHARAMACEUTICAL QUALITY ASSURANCE
COMPLAINT
Reasons
Types of Complaint
Steps involved in Handling of complaints
Product Complaint Data Sheet
Complaint Record
Regulatory Guidelines
SOP on Complaint Handling
RECALL
Reasons
Types of Recall
Recall Classification
Levels of Recall
How to Recall the Product?
How To Notify The Consumers?
Regulatory Guidelines
SOP on Product Recall
DRUG RECALL IN 2013 AND 2014
Presentation on customer focus / customer satisfactioon , customer delight and customer complaints handling. In a sense, customer service attains importance within the context of customer focus. In customer focus, the company puts great emphasis on customer success and customer happiness while customer service is one of the various activities to ensure customer happiness.Make the Effort to Follow-up. Some customer service situations require a follow-up contact. ...
Use Clear Language. It's easy to fall into the trap of using unclear language. ...
Do the Time Zone Math. ...
Anticipate Hidden Needs. ...
Use the Pre-Emptive Acknowledgement. ...
Take the Thank You Letter Challenge. ...
Take Action!
10 Steps to Create a Customer-Focused Culture
Define the culture. If you want to have a customer-centric culture, think about exactly what it should look like. ...
Communicate the culture. ...
Hire the right people. ...
Train your people right. ...
5. Make the training inclusive. ...
Be an example. ...
Empower employees to succeed. ...
Give recognition.
The orientation of an organization toward serving its clients' needs. Having a customer focus is usually a strong contributor to the overall success of a business and involves ensuring that all aspects of the company put its customers' satisfaction first.
Handling of Customer Complaint_Dr.A.AmsavelDr. Amsavel A
Reference Guideline
Definitions
GMP Requirement: 21 CFR § 211.198 and ICH Q7
Procedure for Handling of Complaints
Complaint Investigation
Remedial action and CAPA
Report preparation
Response to customer
Verification of CAPA effectiveness
Review of Complaints
Complaints in Quality Management SystemMayuriMore15
Complaints evaluation and handling, Investigation and Determination, CAPA and Return and Recall of products in Quality Management system in pharmaceutical or any industry.
Market or Customer complaint is “an expression of dis-satisfaction on a customer’s behalf to a responsible party” when their expectations have not been met! However, Complaint handling is a Good Manufacturing Practice (GMP) requirement, since all complaints concerning potentially defective products must be carefully reviewed according to a written procedure.
Similar to A COMPLETE STUDY ON COMPLAINTS, DRUG RECALL, RETURNED PRODUCTS, AND WASTE DISPOSAL (20)
A detailed study on every aspects of parenteral :- introduction, preformulation factors, essential requirements, vehicles and additives, isotonicity, production procedure, facilities, and controls, container and closure selection and finally the quality control evaluation of parenterals.
HISTORICAL BACKGROUND & DEVELOPMENT OF PROFESSION OF PHARMACYTeny Thomas
The following presentation deals with what the course of pharmacy is and what a pharmacist is. Also a short brief on the historical growth of the profession of pharmacy when related to education and industry is also discussed here. A detailed view on career in pharmacy is described lastly.
A comprehensive interpretation of pellets based on their definitions, advantages, disadvantages, mechanism of pellet formation and growth, pelletization techniques, formulation requirements, and the equipment system for manufacture of pellets.
In the manufacture of pharmaceuticals, encapsulation refers to a range of dosage forms—techniques used to enclose medicines—in a relatively stable shell known as a capsule, allowing them to, for example, be taken orally or be used as suppositories. The two main types of capsules are:
Hard-shelled capsules, which contain dry, powdered ingredients or miniature pellets made by e.g. processes of extrusion or spheronization. These are made in two halves: a smaller-diameter “body” that is filled and then sealed using a larger-diameter “cap”.
Soft-shelled capsules, primarily used for oils and for active ingredients that are dissolved or suspended in oil.
The presentation deals with a detailed study of soft gelatin capsules. this involves the production of soft gelatin capsule based on the importance of base adsorption factor and minim/gram factor. also quality control studies was also elaborated.
Hard gelatin capsules - a detailed studyTeny Thomas
The presentation involves a descriptive study on hard gelatin capsules which includes the production of the hard gelatin capsule shell, size of the capsules, capsule filling machines and the finishing techniques. The presentation also involves the special techniques of capsule formulation and the quality control tests of hard gelatin capsules
Everyone requires a product of the best quality, be it in case of medicines or any other edibles or services. Hence, the presentation deals with the quality control of tablets
A detailed study on Tablets which describes about tablets, coating of tablets and then a study on the quality control of tablets. The chapter deals with the minute aspects of tablets and gives us an enlightenment of the solid dosage form which is commonly used all around the world
A detailed study on tablets, its classification, excipients, tablet granulation, methods of granulation, compression machines, equipment tooling and the problems that occur during the tablet manufacturing process. This presentation is based on the PCI syllabus for bpharm students of fifth semester.
The chapter deals with the preformulation studies that have to be considered while designing a dosage form and developing a formulation that is suitable for a patient. Here, physical and chemical properties of a drug substance are studied along with biopharmaceutical classification of drugs. Also a detailed study on the application of preformulation studies in different dosage forms are also studied.
A detailed study on the guidelines that are taken for ICH which is also known as the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. The chapter deals with an overview of Quality, Safety, Efficacy and Multidisciplinary guidelines and then a detailed study on the Quality Guidelines. Also a detailed learning of Stability Testing Guidelines proposed by the International Conference for Harmonization.
A Study on Documentation Maintenance in the Pharmaceutical Industry which includes the main records to be maintained and the quality attributes to be studied about the Quality Management System. Quality attributes include the study of quality audit, quality review, and quality documentation.
A study on waste disposal in the pharmaceutical areas. the chapter deals with types of waste, how the waste is disposed, the procedure of waste disposale and the regulatory guidelines.
Introduction to AI for Nonprofits with Tapp NetworkTechSoup
Dive into the world of AI! Experts Jon Hill and Tareq Monaur will guide you through AI's role in enhancing nonprofit websites and basic marketing strategies, making it easy to understand and apply.
A Strategic Approach: GenAI in EducationPeter Windle
Artificial Intelligence (AI) technologies such as Generative AI, Image Generators and Large Language Models have had a dramatic impact on teaching, learning and assessment over the past 18 months. The most immediate threat AI posed was to Academic Integrity with Higher Education Institutes (HEIs) focusing their efforts on combating the use of GenAI in assessment. Guidelines were developed for staff and students, policies put in place too. Innovative educators have forged paths in the use of Generative AI for teaching, learning and assessments leading to pockets of transformation springing up across HEIs, often with little or no top-down guidance, support or direction.
This Gasta posits a strategic approach to integrating AI into HEIs to prepare staff, students and the curriculum for an evolving world and workplace. We will highlight the advantages of working with these technologies beyond the realm of teaching, learning and assessment by considering prompt engineering skills, industry impact, curriculum changes, and the need for staff upskilling. In contrast, not engaging strategically with Generative AI poses risks, including falling behind peers, missed opportunities and failing to ensure our graduates remain employable. The rapid evolution of AI technologies necessitates a proactive and strategic approach if we are to remain relevant.
Palestine last event orientationfvgnh .pptxRaedMohamed3
An EFL lesson about the current events in Palestine. It is intended to be for intermediate students who wish to increase their listening skills through a short lesson in power point.
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...Levi Shapiro
Letter from the Congress of the United States regarding Anti-Semitism sent June 3rd to MIT President Sally Kornbluth, MIT Corp Chair, Mark Gorenberg
Dear Dr. Kornbluth and Mr. Gorenberg,
The US House of Representatives is deeply concerned by ongoing and pervasive acts of antisemitic
harassment and intimidation at the Massachusetts Institute of Technology (MIT). Failing to act decisively to ensure a safe learning environment for all students would be a grave dereliction of your responsibilities as President of MIT and Chair of the MIT Corporation.
This Congress will not stand idly by and allow an environment hostile to Jewish students to persist. The House believes that your institution is in violation of Title VI of the Civil Rights Act, and the inability or
unwillingness to rectify this violation through action requires accountability.
Postsecondary education is a unique opportunity for students to learn and have their ideas and beliefs challenged. However, universities receiving hundreds of millions of federal funds annually have denied
students that opportunity and have been hijacked to become venues for the promotion of terrorism, antisemitic harassment and intimidation, unlawful encampments, and in some cases, assaults and riots.
The House of Representatives will not countenance the use of federal funds to indoctrinate students into hateful, antisemitic, anti-American supporters of terrorism. Investigations into campus antisemitism by the Committee on Education and the Workforce and the Committee on Ways and Means have been expanded into a Congress-wide probe across all relevant jurisdictions to address this national crisis. The undersigned Committees will conduct oversight into the use of federal funds at MIT and its learning environment under authorities granted to each Committee.
• The Committee on Education and the Workforce has been investigating your institution since December 7, 2023. The Committee has broad jurisdiction over postsecondary education, including its compliance with Title VI of the Civil Rights Act, campus safety concerns over disruptions to the learning environment, and the awarding of federal student aid under the Higher Education Act.
• The Committee on Oversight and Accountability is investigating the sources of funding and other support flowing to groups espousing pro-Hamas propaganda and engaged in antisemitic harassment and intimidation of students. The Committee on Oversight and Accountability is the principal oversight committee of the US House of Representatives and has broad authority to investigate “any matter” at “any time” under House Rule X.
• The Committee on Ways and Means has been investigating several universities since November 15, 2023, when the Committee held a hearing entitled From Ivory Towers to Dark Corners: Investigating the Nexus Between Antisemitism, Tax-Exempt Universities, and Terror Financing. The Committee followed the hearing with letters to those institutions on January 10, 202
Unit 8 - Information and Communication Technology (Paper I).pdfThiyagu K
This slides describes the basic concepts of ICT, basics of Email, Emerging Technology and Digital Initiatives in Education. This presentations aligns with the UGC Paper I syllabus.
Biological screening of herbal drugs: Introduction and Need for
Phyto-Pharmacological Screening, New Strategies for evaluating
Natural Products, In vitro evaluation techniques for Antioxidants, Antimicrobial and Anticancer drugs. In vivo evaluation techniques
for Anti-inflammatory, Antiulcer, Anticancer, Wound healing, Antidiabetic, Hepatoprotective, Cardio protective, Diuretics and
Antifertility, Toxicity studies as per OECD guidelines
Synthetic Fiber Construction in lab .pptxPavel ( NSTU)
Synthetic fiber production is a fascinating and complex field that blends chemistry, engineering, and environmental science. By understanding these aspects, students can gain a comprehensive view of synthetic fiber production, its impact on society and the environment, and the potential for future innovations. Synthetic fibers play a crucial role in modern society, impacting various aspects of daily life, industry, and the environment. ynthetic fibers are integral to modern life, offering a range of benefits from cost-effectiveness and versatility to innovative applications and performance characteristics. While they pose environmental challenges, ongoing research and development aim to create more sustainable and eco-friendly alternatives. Understanding the importance of synthetic fibers helps in appreciating their role in the economy, industry, and daily life, while also emphasizing the need for sustainable practices and innovation.
Operation “Blue Star” is the only event in the history of Independent India where the state went into war with its own people. Even after about 40 years it is not clear if it was culmination of states anger over people of the region, a political game of power or start of dictatorial chapter in the democratic setup.
The people of Punjab felt alienated from main stream due to denial of their just demands during a long democratic struggle since independence. As it happen all over the word, it led to militant struggle with great loss of lives of military, police and civilian personnel. Killing of Indira Gandhi and massacre of innocent Sikhs in Delhi and other India cities was also associated with this movement.
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
A COMPLETE STUDY ON COMPLAINTS, DRUG RECALL, RETURNED PRODUCTS, AND WASTE DISPOSAL
1. COMPLAINTS, RECALLED
GOODS, RETURNED
GOODS, AND WASTE
DISPOSAL
Ms. TENY SARA THOMAS
MOUNT ZION COLLEGE OF PHARMACEUTICAL
SCIENCES AND RESEARCH, ADOOR, KERALA
ASSISTANT PROFESSOR
B.PHARM SIXTH SEMESTER
PHARMACEUTICAL QUALITY ASSURANCE
UNIT IV – CHAPT1
2.
3. COMPLAINTS
Despite all the precautions taken, some
problems may occur in a given drug
product.
The customer finds the faults in the
product.
And the dissatisfaction is conveyed in the
form of a COMPLAINT.
Complaints are then investigated and
corrective actions are taken.
4. DEFINITION
Complaint is defined as statement that is
something wrong or not good enough,
which shows customer dissatisfaction
about the company and the product.
Example: complaining about the drug
product or the packaging materials etc.
All complaints concerning defective
products should be carefully reviewed
according to written procedures.
5. NEED FOR COMPLAINT HANDLING
Gives the company an opportunity to improve
the quality of the product.
Helpful to maintain cGMP.
Maintains committed relationship between the
customer and company.
Reduce costs and improve production
schedules.
Reduce employee confusion.
Improve safety and performance of devices.
6. CLASSIFICATION OF COMPLAINTS
A. CRITICAL COMPLAINTS
Individual defects which can be critical and require the
company to take in need of attention action by all
reasonable resources, whether in and out of company
hours.
Example: microbial contamination of a sterile product.
B. MAJOR COMPLAINTS
These complaints will possibly put the patient at a little
hazard but are not life threatening and will require
product recall within a few days.
example: any labelling/leaflet misinformation.
C. MINOR DEFECTS
Complaints which present only a significant risk to patient.
Example: readily visible inaccessible packaging/closure faults.
7. STEPS TO HANDLE COMPLAINTS
Good Complaint Handling Procedure are
implemented by steps which are divide into
four.
1. Receiving Complaints
2. Technical Investigation
3. Corrective and Preventive Actions(CAPA)
/ Feedback to Customers.
4. Trend Analysis / Monthly Reports
8. RECEIVING COMPLAINTS
Complaints must provide open channels
through which customers can arise their
complaints
The company must appoint a person who
will be responsible for receiving the
complaint, and documenting it as per
company requirements.
The most flexible channels are toll-free
numbers and chat-rooms.
10. TECHNICAL INVESTIGATION
Once the complaint has been received, a
complaint investigation form should be
prepared with the following information:-
Name and contact details of complainant.
Details of the drug product on which
complaint has been raised – product name,
manufacturing batch number, lot number,
manufacture and expiry dates, quantity of
product where problem is seen
Details of the nature of complaint – what
exactly is wrong and has been complained
about.
11. Product complaint data sheet details include:-
Serial number of complaint
Complaint details
Name and address of the complainant.
Date of receiving the complaint
Name of the person who received the complaint.
Details of the product – name, strength, batch number
Size of sample obtained from the complainant.
Complaint evaluation report.
Name and sign of the investigators with date.
Action taken report
Copy of written response sent to complainant.
12. All this information is sent to the Quality
Assurance department to start investigation. A
QA officer is appointed as Complaint Officer
to oversee the next stages.
Two phases of investigation will follow:-
1. Document Based investigation
2. Laboratory Analysis
13. DOCUMENT BASED INVESTIGATION
This involves review of :-
Complaint files to see how many previous
complaints of a similar nature have occurred,
and how the complaints were handled.
Batch manufacturing and packaging records
to check for any incidents of non-
conformance during that particular batch’s
processing.
14. LABORATORYANALYSIS
This phase involves analysis by the Quality
Control laboratory. The samples received
with the complaint as well as the samples
that have been retained by the manufacturer
must be tested and the results are
documented.
The Complaint Officer compares the results of
the laboratory analysis and the document
based investigation and prepares a report that
may result in one of the conclusions:-
• Confirmed complaint
• Non – Confirmed complaint
• Counterfeit/ Tamper Suspicion
15. Confirmed Complaint – when out of specification
(OOS) results are seen in both complaint and
retained or in only complaint samples. For e.g. if
both samples of tablets showed discolouration, o
one tablet is missing from blister pack.
Non Confirmed Complaint – when both retained
and complaint samples test results comply with
specifications, or if complaint samples show OOS
results. For e.g. tablets in complaint sample are
discoloured but not in retained samples.
Counterfeit/ tamper suspicion – when retained
sample meets specifications but complaint
samples are OOS, with no possible reason to
explain the deviation. For e.g. if packing material
of complaint sample is different from the retained
– counterfeit drug. Or if colour of complaint
sample is totally different from retained –
tampered drug.
16. The Complaint Officer investigates if the
complaint involves any unexpected or
serious adverse drug reaction.
After complaint of investigation,
generally within 30 days of receiving the
complaint, the report is prepared and
signed by Complaint Officer and QA
manager.
the complaint file must be maintained for
at least 1 year following the expiry date
of the productive batch.
17. QA
COMPLAINT
OFFICER
Quality Assurance
department to start
investigation. The
Complaint Officer
investigates if the complaint
involves any unexpected or
serious adverse drug
reaction.
STEP 2
1.DOCUMENT
BASED
INVESTIGATION
2.LABORATORY
ANALYSIS
COUNTERFEIT/
TAMPER SUSPICION
NONCONFIRMED
COMPLAINT
CONFIRMED
COMPLAINT
18. CORRECTIVE & PREVENTIVE ACTIONS/
FEEDBACK TO CUSTOMER
In case of confirmed complaints, company
must implement corrective actions depending
on the severity of the problem.
A team of representatives from Production, QC,
QA and higher management areas is put
together for launching CAPA
In case of non confirmed complaints, that
may have originated from improper handling ,
company sends a written response to the
complainant, including information on the
corrective method adopted. Also a free
replacement is sent to the customer.
In case of therapeutic complaints or ADR,
the company may decide for a product recall, if
they see a risk in sale of drug.
19. CORRECTIVE ACTION
•Depend on nature of complaint
•Training
•CAPA procedures
•Product recall
STEP 3
FEEDBACK TO THE CUSTOMER
•Explanation letter to customer about the results
and reason.
•Delivery of free product as reimbursement.
20. TREND ANALYSIS/MONTHLY
REPORTS
Monthly reports should be elaborated in order
to evaluate the amount and the nature of
complaints received and to perform a trend
analysis of these complaints.
The monthly report must answer the
following:-
◦ How many complaints did the company
receive in the period?
◦ How many were confirmed, nonconfirmed
or counterfeit/tamper suspicion?
21. Graphic methods of displaying data are
important adjuncts to data analysis and
presentation.
The report must be readily available mainly
during GMP inspections.
STEP 4
TREND ANALYSIS
•Number of reports :- category, nature, segment,
batches
•Identification and implementation of corrective
actions.
•Sharing of report with all departments.
22. DOCUMENTATION OF FINAL REPORT
ONCOMPLAINTS
Nature of the complaint:- ____________
Date:- __________
Complaint:- _________________
Originator of the complaint& title:-
_____________
Distributor contact person & title:- __________
Method of notification:- ______________
Name:- ____________
Phone No:-________ P.O - ______
Date shipped:- __________ Invoice:-
_______
Product name:-__________ Control No.:-
____
Expiry date:__________ Quantity
involved:-____
23. Total quantity shipped- ________
Reason for complaint return request-
_________
Evaluation of complaints: -
physical characteristics
sign of deterioration
other observation
Quality control findings:-
returned sample
returned sample re assay
initial data
quality control comments &
suggestions
Packaging or labelling or inserts
evaluation.
24. Resultant action taken:
1. Method, date of customer notification &
authorized:- _________
2. Comments:- ___________
3. Completion date for action taken:-
___________
4. Quality assurance evaluation:-_____________
CUSTOMER COMPLAINT RECORD BOOK
REPORT
NO.
DATE
RECEIVED
PRODUCT
NAME
RECEIVED
BY
PRODUCT
LOT NO.
DATE
INVESTIG
ATION
STARTED
DATE
INVESTIG
ATION
ENDED
25. REGULATORY GUIDELINES
A SOP should be available giving full details about
how to handle products complaints and necessary
records about complaints should be maintained.
A person should be designated for handling the
complaints and deciding the measures to be taken
Person should be normally be from quality
management department.
All decisions and measures taken as a result of a
complaint should be recorded
If product defect is suspected in a batch, other
batches should also be checked in order to
determine whether they are also affected.
Written records shall be maintained for at least 1
year after the date that the complain was received.
26.
27. WHAT IS DRUG RECALL?
A process for withdrawing or removing a
pharmaceutical product from the pharmaceutical
distribution chain because of defects in the
product, complaints of serious adverse reactions to
the product or concerns that the product is
counterfeit. The recall might be initiated by the
manufacturer, wholesale dealer license holder or
the Department of Health.
28. OBJECTIVES OF A DRUG
RECALL
To stop the distribution and sale of the
affected product.
Effectively notify management, customers
and regulatory authority.
Efficiently remove the affected product
from the market place, warehouse or
distribution areas.
Dispose and conduct a root cause analysis
and report the effectiveness and outcome of
the recall.
Implement a corrective action plan to
prevent another recall.
29. According to Central Drugs Standard
Control Organisation (CDSCO),
quality defects may include,
Drugs of not standard quality
Spurious or adulterated drugs
Drugs manufactured under cancelled
or suspended license.
Drugs manufactured despite being
prohibited under the provisions of the
Drugs & Cosmetics Act
30. REASONS FOR DRUG RECALL
Potentially dangerous or serious product quality
issues have come to light through complaints.
Mandatory regulations have been violated and
come to the notice of regulatory agency.
Labelling errors and incorrect outer packing.
Lack of assurance of sterility and drug stability.
Misbranded drug
Lack of efficacy, failing dissolution test
requirements, microbial contamination in
products
New information comes into light after
distribution of product indicates it is unsafe or
ineffective or dangerous.5
31. CLASSIFICATION OF DRUG
RECALL
The CDSCO classifies Recalls into three categories:-
CLASS I – is the situation in which there is
reasonable probability that the use of a defective
product will cause serious adverse health
consequences or death.
Recalls under this class must be executed to the
level of distributor/wholesaler, retailer and
consumer.
Public announcements shall be made using print and
electronic media
Timeline for recall ranges from within 24-72hours
Stopping the sales or distribution must be done
within – 24hours
Physical recall must be completed within – 72hours.
E.g. – wrong active ingredient, wrong strength.
32. CLASS II – is the situation in which use of
defective product may cause temporary adverse
health consequences
Probability of serious ADR is remote.
Recall is limited at level of distributor/
wholesaler.
Time limit for recall is within – 10 days. E.g.-
mislabelling.
CLASS III – is the situation in which the use of
defective product is not likely to cause any
adverse health consequences.
Recall is executed until the wholesaler level.
Time limit – 30days. E.g. – faulty closure,
wrong expiry date.
Banned drugs for which license is cancelled or
suspended, if found to be in the market, shall
have to be recalled, - being treated as CLASS
I
33. TYPES OF DRUG RECALL
Product recall may be of two types:-
A) Voluntary Recall
refers to situations when manufacturer
decides on their own initiative to recall
products where the safety, efficacy and
quality of batch is in question
E.g 1. – an in-house reveals a failure that
can cause adverse effect on the quality of
a batch of products that has been
distributed.
E.g 2. – market complaints investigation
show that the entire batch is defective.
E.g 3. – visual inspection of retained show
evidence of deterioration that has an
impact on product quality.
34. B) Statutory Recall
refers to recalls mandated by drug
regulatory bodies at Central or State
levels for one of the reasons
E.g 1. – product violates the law – not
of standard quality.
E.g 2. – formulation contains banned
drugs.
E.g 3. – labelling of product or
promotional material violates the law.
E.g 4. – product claims to treat diseases
mentioned in Schedule J (claims to
cure a disease that no drug can)
35. PRODUCT RECALL SYSTEM
Every company is required to have a product
recall system in place to effect a prompt and
effective recall in case of serious complaints
regarding defective products.
As per cGMP guidelines, product recall
activities must be coordinated and executed by
an authorized person who is independent of the
marketing and sales function of the company.
The recall approving authority is generally the
Head of the Company
(President/Proprietor/Managing Director).
Recall strategy must be prepared which is a
planned specific course of action to be taken in
conducting a specific recall.
36. Recall strategy details must include information
regarding:
Authorized person who will initiate the recall.
Nature of communication that will be used to
initiate recall (telephone, email, letters etc.).
Depth of the recall to be instituted (recall from
distributor/wholesaler/hospital/ retailer/general
public).
Manner of receiving, segregating and secure storage
of the recalled product.
Satisfying reports to be prepared, at what
frequency.
Verification of success of recall and report
submission to regulatory authorities.
Steps to be taken to avoid re-occurrence of the
same issue with the product.
Dealing with recalled product – reworking or
destruction as may be appropriate
37. PRODUCT RECALL TEAM
A recall coordinator is to be appointed and
members of a recall team identified from
the various functional areas.
All members must ensure that all
procedures are carried out effectively and
efficiently. The team should receive
appropriate training.
Recall management team list shall be
updated at least four times a year.
Chief executive officer – decision making,
media communication.
Quality assurance manager – quality or
technical advisory, complaint investigation
38. PRODUCT RECALL
PROCEDURE
For potentially violative product that
may lead to a Class I or II recall, an
inspection should be made to determine
the root causes of the problems.
The suspected problem is discussed
with the management and reviewed.
Review batch records, or other types of
records for violative lots.
Determine what actions the firm has
taken or plans to take.
39. If the firm has decided to recall,
Management should obtain the FDA’s
district review of recall and any press
releases before they are issued to prevent
misunderstandings between the firm, its
customers, and FDA.
Obtain an official sample of the recalled
product, a complete distribution list of all
shipments of the suspect lot, specimens pr
copies of all labels.
Obtain complete copies of all recall
communications issued or planned
including phone or text conversations, and
submit them to districts recall coordinator.
40. STAGES OF PRODUCT RECALL
1. Recall alert
2. Recommendation for recall number
3. Recall product
4. Code
5. Recalling firm/ manufacturer
6. Reasons for recall
7. Volume of product in commerce
8. Distribution pattern
9. Firms recall strategy
10. Firm official
11. Audit program
12. Monitoring recalls
13. Termination of recall
14. Close out inspection
41. 1. Recall alert:- a 24hour alert is given for
the product recall.
2. Recommendation for recall number - a
memorandum should be prepared as soon
as the recall number is available
3. Recall product – its name, type, strength,
size, form, route of administration, brief
description of the product whether it is
OTC or prescription based.
4. Code – list of all lot/serial number,
product number, manufacturer number
which appears on the product label.
5. Recalling firm – provide complete name
& address of the recalling firm & identify
the type of firm i.e., manufacturer,
importer, etc.
42. 6. Reasons for recall – a detailed information
based on the analytical findings in
qualitative or quantitative terms,
inspectional evidences, or complaints,
injuries that prove the product is defective.
7. Volume of Product in Commerce – total
product distributed at all levels.
8. Distribution pattern – report the areas of
distribution of products to the local areas
of all levels, foreign countries,
government military agencies.
9. Firms recall strategy – describes the
firm’s planned recall strategy. Includes the
date of initiation of recall.
43. 10. Firm Official – report the name, title,
location, and telephone number of the firm
official to be contacted concerning the
recall.
11. Audit program – report appropriate
action taken & also provide details of any
publicity issued or planned by the firm,
state or local govt.
12. Monitoring recalls –
a. Re-inspect the firm between and
termination of recall to monitor its
progress
b. A recall audit check is a personal visit or
phone call to consignee from a recalling
firm in the chain of distribution.
44. c. Conducting the check –
Details of the recall
Recall strategy
Amount of product recalled till date
Visit storage sites of the recalled product,
check shelf stock to ensure all recalled
product has been identified, removed from
areas and properly quarantined.
If injury or complaint is reported, furnish
the corrective actions taken
Amount of product destroyed, and method
of destruction.
d. Reporting of the audit checking.
45. 13. Termination of recall - a recall will be
terminated if efforts have been made to
remove or correct the violative product in
accordance with the recall strategy.
Written notification that a recall is
terminated will be issued by the authority
to the recalling firm.
14. Close out inspection – a limited
inspection made to verify the termination
of recall by the recalling firm. During the
closeout inspection, witness destruction or
reconditioning of the recalled product is
done.
If unable to witness the destruction, a
written documentation from firm should
be obtained.
46.
47.
48. Pharmaceutical products may be returned from
the market in case they do not meet their
acceptance criteria or any other various reasons.
E.g. quality problems, accidental damage of
goods. Such products when returned from the
market should have the following actions
immediately taken.
Physically examine the condition of the
returned goods and the relevant documents.
Ask quality control department to evaluate the
quality of the goods received, and take a
decision on whether these products can be
reprocessed and recovered or needs to be
destroyed.
49. If it is possible to reprocess and recover, then
such products after reprocessing and retesting
may be considered for relabeling, repacking
and resealing.
Quality control department should evaluate
all aspects like condition of the received
material, time elapsed since it was first
processed along with microbiological or any
other technical evaluations.
Any action taken should be recorded.
50. For each return of a product, documentation
should include:-
name and address of the consignee
Intermediate or API
Batch number
Quantity returned
Reason for return
Use or disposal of the returned product
51. STANDARD OPERATING PROCEDURE
OF HANDLING RETURNED GOODS
Returned goods shall be received, identified and
stored in the designated area by the warehouse
person with the identification label as “Returned
Goods”.
Warehouse person shall check dispatch
documents and documents received from the
distributor / customer inspect the consignment
and shall record the observation in Returned
Goods verification report. Now this report shall
be sent to Quality assurance department.
52. Quality assurance personnel shall verify the
returned consignment.
If the seal is broken by the customer, the
material shall be sampled from each container
and analysed.
Based on satisfactory evaluation against
specification, decision of release shall be taken
and material can be sent for re-sale.
If results are border line / out of specification
limit then material shall be rejected and
investigation shall be carried out.
53. In case the material is about to expire, then the same
shall be analysed for the identification and shall be
taken for the appropriate reprocessing.
If the material is found to be contaminated, then it
shall be sent for destruction or disposal.
Based on the findings and analytical results of
returned goods, Quality Control department shall
recommend for – reprocessing, repacking,
distribution for sale, or destruction.
This is also informed to the Warehouse for the
further action.
QC department shall maintain record for returned
goods along with its complete set of documents.
54. Sales return no. ___________________
Product name ___________________
Batch no ___________________
Date of return ___________________
Net wt. ___________________
Content No. ___________________
LABELLING OF RETURNED
GOODS
55.
56. Waste includes all items that people no longer have
any use for, which they either intend to get rid of
or have already discarded.
Pharmaceutical waste potentially generated
includes:-
Expired drugs
Patients discarded personal medications
Contaminated garments, absorbents
Syringes, vials, iv bags, tubings
Waste materials containing chemotherapy drug
residues.
Open containers of drugs that cannot be used.
58. A) HAZARDOUS WASTE
Potentially dangerous to human health or environment.
Hazardous wastes can be of two types –
characteristic waste and listed waste.
Characteristic waste – are waste which may have the
following characters :-
Ignitability – identify waste that either present a fire
hazard under routine storage, disposal, and
transportation. E.g. Erthromycin gel.
Corrosivity – any waste which has a pH of less than or
equal to 2 or greater than or equal to 12.5 exhibits the
characteristic of corrosivity. E.g. – glacial acetic acid
Reactivity – waste which can cause explosion, toxic
fumes, gases when heated, compressed etc. E.g. –
nitroglycerine
Toxicity – if the waste leaches in a landfill environment
and the determined level exceeds the stated limits
59. Listed hazardous waste :- wastes from
common manufacturing and industrial process.
These can be of four type :- P, U, F & K.
Pharmaceuticals comes under the P and U list
P list and U list wastes – are chemicals that are
acutely hazardous under Resource Conservation
and Recovery Act. . P listed waste are toxic and
cause death or irreversible illness at low dose.
U- listed waste are identified as toxic wastes.
60. B) NON - HAZARDOUS WASTE
Presents significant hazardous characteristics.
No hazardous components present.
Pharmaceutically inert
C) BIOHAZARDOUS WASTE
Contain pathogens of sufficient virulence and
quantity that exposure to the waste by a
susceptible host could result in an infectious
disease.
Waste includes needles, syringes, pipettes, vials
that may have come in contact with body fluids.
Container must be clearly labelled with
“biomedical”, “infectious waste”
Stored in rigid plastic containers.
61. D) RADIOACTIVE WASTE
High level nuclear waste – reactor fuel
assemblies, solid and liquid waste from fluid
reprocessing.
Low level nuclear waste – that contains
radioactive nuclides emitting beta or gamma
radiation.
E) INERT WASTE
Materials that do not have any therapeutic effect
but they are used for supportive nutrition. E.g.
sodium chloride solution.
They may become mixed with other chemicals.
Checked for hazardous properties before
disposal
62. F) CHEMO WASTE
Classified as Trace Chemotherapy and Bulk
Chemotherapy
Trace Chemotherapy Wastes include;-
1. gowns, gloves, wipes, associated with
routine handling, preparation and administration
of chemotherapy
2. wipes and other materials used during
cleaning and decontamination of a biological.
Bulk Chemotherapy Waste – any
chemotherapy waste that is not deemed RCRA
empty.
E.g. any item used to clean up a chemo spill.
64. 1. INCINERATION
Solid organic waste are incinerated or burnt
to convert them into gaseous products and
a solid residue in the form of ash
Best ways to dispose hazardous wastes
Suitable for highly reactive chemicals like
halogens.
Ash produced after incineration must be
disposed into a secure landfill.
Arrangements for preventing air pollution
from the gas produced during the process.
65. 2.WASTE IMMOBILISATION -
ENCAPSULATION
Encapsulation involves immobilising
pharmaceuticals in a solid block within a
plastic or steel drum.
Drums should be cleaned prior to use and
should not have contained explosive or
hazardous materials previously.
They are filled to 75% capacity with solid and
semisolid pharmaceuticals. The remaining
space is filled with cement, lime, plastic.
The drums are sealed by spot welding, placed
at the base of a landfill and covered with fresh
solid waste.
66. 3.WASTE IMMOBILISATION -
INERTIZATION
Inertization is a variant of encapsulation
and involves removing the packaging
materials, paper, cardboard and plastic
from pharmaceutical products.
Pharmaceutical products are ground and a
mix of water (5%), cement (15%), and lime
(15%) is added to form a homogenous
paste.
The paste is transported by concrete mixer
truck to a landfill and decanted into the
normal urban waste.
67. 4. CHEMICAL DISINFECTION
Treating waste materials with chemicals
that will inactivate the chemicals or
biological materials present in the liquid
waste.
Effectiveness of the process depends on the
type of chemical used, its concentration,
and nature of contact between disinfectant
material and waste.
68. 5. MICROWAVING
Includes the use of microwave radiation
and can destroy the infectious materials in
the biological waste.
Electricity requirement is less and steam is
not needed.
Waste materials required to be shredded
prior to microwaving in order to allow the
radiation to come into contact with the
waste material.
69. 6. AUTOCLAVING
Saturated steam is passed through the
waste in the autoclave for a duration and at
a temperature sufficient to destroy the
pathogens.
Commonly used for biomedical waste
disposal and waste generated from the
microbiological testing laboratory.
After autoclaving, the waste is disposed by
land filling.
Not best for chemical and drug product
waste.
70. 7. DEEP BURIAL
Waste is buried in deep pits that are at least 2
metres deep.
One must ensure that the soil is impermeable
in these areas and that there are no shallow
wells in the area to avoid the risk of water
contamination.
Half the pit is covered with the biomedical
waste and rest is filled with lime, stopping
50cm below ground surface.
Final layer of the pit is made up of soil to
cover the waste.
Such burial should be done in area not prone
to flooding.
71. 8. SECURE LAND FILLING
Waste are disposed by burying in landfills
that has been designed to contain
hazardous wastes.
If not properly designed and operated, the
landfill may lead to liquid leaching into the
ground water, attraction of vermin etc.
Also gas extraction systems must be
available for the removal of carbon dioxide
and methane that has produced by the
anaerobic breakdown of the waste.
72. 9. SEWER TREATMENT
Some liquid pharmaceuticals can be diluted
with water and flushed into the sewers in
small quantities without serious public
health or environmental affect.
74. WASTE MINIMIZATION
Prevention of waste material from being created –
waste reduction.
There are limitations of substituting hazardous
substances with lesser hazardous substances as the
hazardous substances are of more therapeutic effect.
Priming and flushing IV lines with saline solution.
Maximising the use of open chemotherapy vials.
Replacing pre-packaged unit dose liquids with patient
specific oral syringes.
Reuse of second hand products, repairing broken items,
designing products to be refillable or reusable.
Develop a detailed organisation’s approach to
identifying drugs that must be managed as hazardous
waste.
Training the staff about minimizing wastage.
75. REUSE
Use of a product on more than one occasion, either for
same or different purpose.
Avoids discarding a material to waste stream when its
initial use has concluded.
E.g. returnable plastic pellets
Using empty glass jar for storing items
Using second hand clothes.
RECYCLING
Involves treatment or reprocessing of a discarded waste
material to make it suitable for subsequent reuse either
for its original or for other purposes.
Recycling benefits the environment by reducing the use
of virgin materials.
In the European Union, 13% waste is recycled.
76. ENERGY RECOVERY
Energy content of waste products can be harnessed
directly by using them as direct combustion fuel.
Thermal treatment ranges from using waste as a fuel
source for boilers to generate steam and electricity.
Waste materials are heated to high temperatures with
limited oxygen availability.
77. WHO GUIDELINES
Provision should be made for proper and safe
storage of waste materials awaiting disposal.
Toxic substance and flammable materials
should be stored in suitably designed,
separate, enclosed cupboards as required
national legislation.
Waste materials should not be allowed to
accumulate. It should be collected in suitable
hollow object for removal from collection
points outside the building and disposed off
safely and in a sanitary manner at regular and
frequent interval.
78. WASTE PRODUCT DISPOSAL
PROCEDURE
1. Any product requiring disposal should initially be
separated from its packaging.
2. Identify drugs that must be managed as hazardous
waste.
3. Determining which non-regulated drugs will be
managed as hazardous waste.
4. Labelling drugs to facilitate segregation of
hazardous waste.
5. Preparing and maintaining hazardous waste
manifests.
6. Determining their hazardous waste generation
status and what criteria are used for hazardous
waste selection.
7. Scheduling regular program reviews and keeping
management informed.
79. RECORDS
Keep it for at least 3 years for following:-
License applications
Licenses
Land disposal restriction forms
Inspection logs
Recycled waste shipping papers
Emergency response record
Analytical reports
All data used in evaluations
Training documents
Editor's Notes
Resource conservation and recovery act – RCRA
RCRA emoty